Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Viatris“
Suchtreffer
Begriffe & Kennungen
Ambrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Peripheral oedema (37%) and headache (28%) were the most common adverse reactions observed with ambrisentan. T
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Reductions in haemoglobin concentrations and haematocrit (10%) have been associated with ERAs including ambris
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Serious adverse reactions associated with ambrisentan use include anaemia (decreased haemoglobin, decreased ha
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Summary of the safety profile
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · System organ class Frequency Adverse reaction(s) Blood and lymphatic system Very common Anaemia (decreased hae
Eintrag öffnenAmbrisentan Viatris (previously Ambrisentan Mylan) · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma)
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.1 Therapeutic indications · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.3 Contraindications · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 6.1. S
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · 6 Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitan
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · 7 (loading dose) and 40% (maintenance dose). The decrease was associated with a 39% (loading dose) and 21% (ma
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · 8 As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay and red
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · A significantly reduced platelet inhibition has been shown in HIV patients treated with ritonavir-or cobicista
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet agg
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnen